| Drug Type Small molecule drug | 
| Synonyms MT 101 (Morphic Therapeutic), MT 101 (Morphic Therapeutic, Inc.), MT101 (Morphic Therapeutic) | 
| Target | 
| Action antagonists | 
| Mechanism α4β7 antagonists(Integrin alpha-4/beta-7 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Inflammatory Bowel Diseases | Preclinical | United States  | 22 May 2022 | 





